BioStem Technologies, Inc. (OTCMKTS:BSEM) Short Interest Up 41.1% in September

BioStem Technologies, Inc. (OTCMKTS:BSEM) saw a large growth in short interest in September. As of September 30th, there was short interest totalling 88,600 shares, a growth of 41.1% from the September 15th total of 62,800 shares. Based on an average daily volume of 57,200 shares, the short-interest ratio is currently 1.5 days.

BioStem Technologies Stock Down 2.3 %

Shares of OTCMKTS:BSEM traded down 0.26 during trading on Monday, hitting 10.89. The stock had a trading volume of 21,900 shares, compared to its average volume of 27,344. The stock has a 50-day simple moving average of 10.56 and a two-hundred day simple moving average of 9.79. BioStem Technologies has a 12-month low of 2.26 and a 12-month high of 15.50. The stock has a market capitalization of $177.29 million, a price-to-earnings ratio of 27.91 and a beta of 0.05.

BioStem Technologies (OTCMKTS:BSEM) last posted its earnings results on Monday, August 12th. The company reported 0.30 earnings per share for the quarter, beating the consensus estimate of 0.12 by 0.18. The company had revenue of 74.49 million during the quarter, compared to analyst estimates of 43.99 million. As a group, sell-side analysts forecast that BioStem Technologies will post 1.13 earnings per share for the current year.

BioStem Technologies Company Profile

BioStem Technologies, Inc, a life sciences corporation, focuses on discovering, developing, and producing pharmaceutical and regenerative medicine products and services. It develops various biologic stem cell based alternative products, as a treatment for ailments, such as joint pain, tendon and ligament injuries, neurodegenerative, and autoimmune diseases.